Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fungi

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    55 result(s) found for: Fungi. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-005003-33 Sponsor Protocol Number: WSA-CS-003 Start Date*: 2008-06-26
    Sponsor Name:Astellas Global Pharma Development, Inc
    Full Title: Open label study of isavuconazole in the treatment of patients with aspergillosis and renal impairment or of patients with invasive fungal disease caused by rare moulds, yeasts or dimorphic fungi.
    Medical condition: Invasive fungal disease caused by Aspergillus species in patients with renal impairment as well as disease caused by rare moulds, yeasts or dimorphic fungi.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10003486 Aspergillus infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) HU (Completed) CZ (Prematurely Ended) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-003868-59 Sponsor Protocol Number: WSA-CS-004 Start Date*: 2011-05-12
    Sponsor Name:Astellas Global Pharma Development, Inc.
    Full Title: A phase III, double blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by Apsergillus species or other fi...
    Medical condition: Invasive fungal disease caused by Aspergillus species or other filamentous fungi.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10003488 Aspergillosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) HU (Completed) ES (Completed) NL (Completed) IT (Completed) GB (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005707-92 Sponsor Protocol Number: 16-03/MicoFlu-C Start Date*: 2016-11-07
    Sponsor Name:Dermapharm AG
    Full Title: Double-blind, randomised clinical study comparing efficacy and safety of Miconazole 2% Fluprednidene 0.1% Cream (Test) vs. Vobaderm® Cream (Reference) vs. Vehicle in patients with moderate to sever...
    Medical condition: moderate to severely inflamed candidiasis of the skin
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10007159 Candidiasis of skin and nails LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001386-33 Sponsor Protocol Number: APX001-202 Start Date*: 2019-08-20
    Sponsor Name:Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer, Inc.
    Full Title: A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients with Invasive Mold Infections Caused by Aspergillus Species or Rare Molds
    Medical condition: Treatment of patients with invasive mold infections (IMIs) caused by Aspergillus species (spp.) or rare molds
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10062642 Invasive mycosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001010-42 Sponsor Protocol Number: 19-01/MicoFlu-C Start Date*: 2019-10-16
    Sponsor Name:Dermapharm AG
    Full Title: Double-blind, randomised clinical study comparing efficacy and safety of Miconazole 2%_Fluprednidene 0.1% Cream (Test) vs. Vobaderm® Cream (Reference) vs. Vehicle in patients with moderate to sever...
    Medical condition: moderate to severely inflamed candidiasis of the skin
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10007159 Candidiasis of skin and nails LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003790-65 Sponsor Protocol Number: 21-01/ClotriBet-S Start Date*: 2022-02-11
    Sponsor Name:Dermapharm AG
    Full Title: Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Ointment (Test) vs. Lotricomb® Ointment (Reference) vs. Vehicle in patients with moderate to severely inflamed ca...
    Medical condition: moderate to severely inflamed candidiasis of the skin
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10007159 Candidiasis of skin and nails LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001290-17 Sponsor Protocol Number: F901318/0032 Start Date*: 2018-03-30
    Sponsor Name:F2G Biotech GmbH (FN 483749 x)
    Full Title: An open-label single-arm Phase IIb study of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi in pat...
    Medical condition: invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Ongoing) NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003416-31 Sponsor Protocol Number: FAEDV-2012-01 Start Date*: 2013-02-22
    Sponsor Name:Fundación Academia Española de Dermatología y Venereología
    Full Title: Multicenter, randomized, open clinical trial comparing three sessions of methyl-aminolevulinate 16% (Metvix®) photodynamic therapy versus a group without photodynamic therapy to treat onychomycosis.
    Medical condition: onychomycosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000801-39 Sponsor Protocol Number: PsAer-IgY Start Date*: 2011-08-31
    Sponsor Name:Mukoviszidose Institute gGmbH
    Full Title: Prospective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention ...
    Medical condition: Cystic fibrosis (CF) is a chronic and progressive genetic disease of the body's exocrine glands. CF especially affects the respiratory system. A common effect leads to massive production of abnorma...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10011764 Cystic fibrosis NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) BE (Completed) IT (Completed) IE (Completed) HU (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000561-31 Sponsor Protocol Number: PM1331 Start Date*: 2015-06-15
    Sponsor Name:Polichem S.A.
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF P-3058 10% NAIL SOLUTION IN THE TREATMENT OF ONYCHOMYCOSIS
    Medical condition: Mild to moderate distal subungual Onychomycosis caused by Dermatophytes
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10030338 Onychomycosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) BG (Completed) SE (Completed) DE (Completed) SK (Completed) BE (Completed) PL (Completed) CZ (Completed) LT (Completed) GR (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2018-002579-16 Sponsor Protocol Number: CF001 Start Date*: 2018-08-26
    Sponsor Name:Karolinska University Hospital, Stockholm CF center
    Full Title: Evaluation of the possible use of analysis of posaconazole in exhaled breath as a surrogate marker for the lung to monitor adequate dosages of posaconazole in CF patients treated for Aspergillus sp...
    Medical condition: Cystic Fibrosis (CF) is the most common life–limiting autosomal recessive disease among people of European heritage. The condition is a result of a mutation in the cystic fibrosis transmembrane con...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10074549 Cystic fibrosis respiratory infection suppression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000904-14 Sponsor Protocol Number: MICA_HDF Start Date*: 2012-07-19
    Sponsor Name:Medizinische Universität Wien
    Full Title: PHARMACOKINETICS OF MICAFUNGIN DURING CONTINUOUS VENOVENOUS HEMOFILTRATION
    Medical condition: Suspected or proven candida infection requiring parenteral antifungal therapy
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10042941 Systemic fungal infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003665-10 Sponsor Protocol Number: RBH2017/001 Start Date*: 2020-02-25
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A single-centre study of the relationship between eosinophil activation and the lung microbiome in severe eosinophilic asthma (SEA) and the effect of benralizumab on these factors
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-002408-42 Sponsor Protocol Number: ASPER-III-19-1 Start Date*: 2020-02-07
    Sponsor Name:LABORATOIRES SMB S.A.
    Full Title: A Phase 3, Double Blind, Multicentric, Randomised, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Itraconazole Dry Powder for Inhalation for the Prevention of Invasive ...
    Medical condition: prevention of invasive mould disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10003488 Aspergillosis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) BG (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) BE (Completed) IT (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-019562-91 Sponsor Protocol Number: GS-EU-131-0247 Start Date*: 2010-12-13
    Sponsor Name:Gilead Sciences International Ltd
    Full Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of...
    Medical condition: Invasive fungal infections (IFI) in subjects with Acute Lymphoblastic Leukemia (ALL) undergoing remission induction chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) PT (Completed) ES (Completed) DE (Completed) GR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003717-33 Sponsor Protocol Number: P02095 Start Date*: 2005-09-13
    Sponsor Name:SCHERING-PLOUGH
    Full Title: Open-Label, limited access protocol of Posaconazole in invasive fungal infections.
    Medical condition: Profilaxys of invasive mycotic infections in high risk neutropenic patients.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10017533 PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003087-70 Sponsor Protocol Number: PM1125 Start Date*: 2011-12-02
    Sponsor Name:Polichem SA
    Full Title: Randomized, open-label, controlled study on the efficacy of Ciclopoli® (ciclopirox 8% nail lacquer) versus Loceryl® (amorolfine 5% nail lacquer) on the culture conversion to negative in patients w...
    Medical condition: distal subungual onychomycosis without lunula involvement due to fungal nail pathogens (dermatophytes, white yeasts and/or Scopulariopsis spp. and/or Fusarium spp.) affecting at least one big toenail
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2019-000376-41 Sponsor Protocol Number: VORIGENIPHARM Start Date*: 2019-06-18
    Sponsor Name:Fundación de Investigación del Hospital Universitario La Paz (FIBHULP)
    Full Title: Randomized and multicenter clinical trial to evaluate the effectiveness and efficiency of a voriconazole preemptive genotyping strategy in patients with risk of aspergillosis.
    Medical condition: Invasive fungal disease in the hematologic patient.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10017528 Fungal infectious disorders HLGT
    20.0 10021881 - Infections and infestations 10040054 Sepsis, bacteraemia, viraemia and fungaemia NEC HLT
    20.0 100000004851 10029355 Neutropenias HLT
    20.0 100000004851 10076734 Chemotherapy induced neutropenia LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061187 Haematopoietic neoplasm PT
    20.0 100000004865 10059041 Allogeneic peripheral haematopoietic stem cell transplant LLT
    20.0 100000004865 10059040 Autologous peripheral haematopoietic stem cell transplant LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004356-20 Sponsor Protocol Number: DCS-002 Start Date*: 2011-10-31
    Sponsor Name:Pergamum AB
    Full Title: A randomised, parallel-group, double-blind, placebo-controlled study of DPK-060 to investigate clinical safety and efficacy in patients with acute external otitis
    Medical condition: Acute external otitis (EO)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003784-19 Sponsor Protocol Number: RJ-CPX01 Start Date*: 2017-07-21
    Sponsor Name:Laboratorio Reig Jofre, SA
    Full Title: Phase III, multicentre, randomised, double blind, parallel-group, clinical trial to evaluate the efficacy and safety of a new medicated nail lacquer for the treatment of toenail fungal infection
    Medical condition: toenail onychomycosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10030338 Onychomycosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) LV (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 14:56:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA